TY - JOUR
T1 - Effects of a New Topical Treatment Containing Several Hair Growth Promoters in Women with Early Female Pattern Hair Loss
AU - Vincenzi, Colombina
AU - Marisaldi, Benedetta
AU - Tosti, Antonella
AU - Patel, Brijeshkumar
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Female pattern hair loss (FPHL) is increasing ly common and often presents with hair shedding. Spec tral.DNC-N® contains anti-inflammatory actives and hair growth promoters. Objectives: To assess the efficacy and tolerability of Spectral DNC-N® (DS Laboratories, Inc.) in women with early FPHL and excessive shedding. Methods: Forty-nine patients were treated with Spectral DNC-N®, applied twice daily for 3 months; 28 patients were included in the 3-month treatment extension. Efficacy assessments included the degree of hair shedding using the validated hair shedding visual scale, hair mass index (HMI), and photographic evaluation. Results: There was a statistically significant decrease in hair shedding and a corresponding increase in HMI by month 3, which was maintained through month 6. The mean investigator-assessed hair shedding score decreased from 3.5 to 2.0 and the hair mass increased from 75.8 to 84.3 mm2/cm2 by month 3 (both < 0.01 compared with baseline). By month 6, the hair shedding score was reduced to 1.6 and the hair mass was maintained. Most patients (75%) showed an increase in global hair density. Conclusions: Spectral.DNC-N® significantly reduced hair shedding, with a corresponding increase in hair mass and density. These effects were already evident after 3 months' treatment and further improved in those patients who continued treatment to month 6. Tolerability was good and patient satisfaction levels were high.
AB - Female pattern hair loss (FPHL) is increasing ly common and often presents with hair shedding. Spec tral.DNC-N® contains anti-inflammatory actives and hair growth promoters. Objectives: To assess the efficacy and tolerability of Spectral DNC-N® (DS Laboratories, Inc.) in women with early FPHL and excessive shedding. Methods: Forty-nine patients were treated with Spectral DNC-N®, applied twice daily for 3 months; 28 patients were included in the 3-month treatment extension. Efficacy assessments included the degree of hair shedding using the validated hair shedding visual scale, hair mass index (HMI), and photographic evaluation. Results: There was a statistically significant decrease in hair shedding and a corresponding increase in HMI by month 3, which was maintained through month 6. The mean investigator-assessed hair shedding score decreased from 3.5 to 2.0 and the hair mass increased from 75.8 to 84.3 mm2/cm2 by month 3 (both < 0.01 compared with baseline). By month 6, the hair shedding score was reduced to 1.6 and the hair mass was maintained. Most patients (75%) showed an increase in global hair density. Conclusions: Spectral.DNC-N® significantly reduced hair shedding, with a corresponding increase in hair mass and density. These effects were already evident after 3 months' treatment and further improved in those patients who continued treatment to month 6. Tolerability was good and patient satisfaction levels were high.
KW - Female pattern hair loss
KW - Global photography
KW - Hair growth promoters
KW - Hair mass index
KW - Hair shedding visual scale
KW - Spectral.DNC-N®
UR - http://www.scopus.com/inward/record.url?scp=85054980143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054980143&partnerID=8YFLogxK
U2 - 10.1159/000493200
DO - 10.1159/000493200
M3 - Article
AN - SCOPUS:85054980143
VL - 5
SP - 146
EP - 151
JO - Skin Appendage Disorders
JF - Skin Appendage Disorders
SN - 2296-9195
IS - 3
ER -